


# 25. Jahrestagung der ÖGNR & 12. Erich-Klein-Kurs für interventionelle Neuroradiologie




16.-18. November 2017

Alte Universität Graz



## TAGUNGS PROGRAMM



ÖSTERREICHISCHE  
GESELLSCHAFT FÜR  
NEURORADIOLOGIE  
diagnostisch und interventionell



Medizinische Universität Graz



*MicroVention Welcomes All Attendees to the  
25. Jahrestagung der ÖGNR, Graz, Austria*

**MicroVention® is dedicated to the development of  
innovative neuroendovascular technologies.**



**WEB™**  
With  
MicroBraid™  
Technology

*Simple and versatile solution for  
long lasting treatment in ruptured  
and unruptured aneurysms*



**HydroCoil®**  
Embollic System

*Clinically proven to improve  
patient outcomes through lower  
recanalization rates¹*



**Contact your Local Sales Representative or MicroVention Customer Service for questions  
or to order MicroVention products at: +49 211 210 7980 or [www.microvention.com](http://www.microvention.com).**

**CAUTION:** The WEB™ Aneurysm Embolization System is an investigational device limited by United States law to investigational use.

**INDICATIONS FOR USE**

The WEB™ Aneurysm Embolization System is intended for the endovascular embolization of ruptured and unruptured intracranial aneurysms and other neurovascular abnormalities such as arteriovenous fistulae (AVF). The WEB Aneurysm Embolization System is also intended for vascular occlusion of blood vessels within the neurovascular system to permanently obstruct blood flow to an aneurysm or other vascular malformation. The device should only be used by physicians who have undergone training in all aspects of the WEB Aneurysm Embolization System procedures as prescribed by MicroVention, Inc.

The HydroCoil® Embollic System (HES) is intended for the endovascular embolization of intracranial aneurysms and other neurovascular abnormalities such as arteriovenous malformations and arteriovenous fistulae. The HES is also intended for vascular occlusion of blood vessels within the neurovascular system to permanently obstruct blood flow to an aneurysm or other vascular malformation and for arterial and venous embolizations in the peripheral vasculature. The device should only be used by physicians who have undergone pre-clinical training in all aspects of HES procedures as prescribed by MicroVention.

1. White PM, Lewis SC, Gholkar A et al. Hydrogel coils vs. bare platinum coils for the endovascular treatment of intracranial aneurysms (HELP): a randomized controlled trial. *Lancet* 2011, 377: 1655-1662.

MICROVENTION and HydroCoil are registered trademarks of MicroVention, Inc. WEB and MicroBraid are trademarks of MicroVention, Inc. Refer to Instructions for Use, contraindications and warnings for additional information. © 2017 MicroVention, Inc.

# Willkommen in Graz!



Liebe Kolleginnen und Kollegen!

Es ist mir eine besondere Freude, Sie zur 25. Jahrestagung der Österreichischen Gesellschaft für Neuroradiologie (ÖGNER) und zum 12. Erich-Klein-Kurs für interventionelle Neuroradiologie in Graz begrüßen zu dürfen. Unsere bereits traditionelle Tagung findet heuer in den stilvollen Räumlichkeiten der Alten Universität statt.

Im nunmehr 12. Erich-Klein-Kurs für interventionelle Neuroradiologie werden wir als einen der Schwerpunkte die verschiedensten Aspekte der endovaskulären Schlaganfallbehandlung beleuchten und in bewährter Weise gemeinsam mit zahlreichen anderen ausführlich diskutieren. Betreffend die mechanische Thrombektomie und die endovaskuläre Aneurysma-behandlung können an fünf Stationen Hands-on die Materialien und Methoden unter anderem mit Hilfe von Simulatoren und Modellen geübt und kennengelernt werden. Die Tagung soll Ihnen wie auch in den Jahren zuvor ein Forum reger Diskussion in unterschiedlichen Bereichen der interventionellen Neuroradiologie in überschaubarem Rahmen bieten. Unsere namhaften Referentinnen und Referenten gewährleisten höchstes Niveau und fachliche Expertise.

Die diesjährige Jahrestagung der ÖGNER widmet schwerpunktmäßig den entzündlichen und demyelinisierenden Erkrankungen von Gehirn und Rückenmark sowie den peripheren Nerven. Am Samstag werden die Diffusionsbildgebung und die Traktographie im Vordergrund stehen. Der zeitliche Ablauf soll reichlich Platz bieten, die präsentierten Inhalte ausführlich zu diskutieren.

Im Namen des lokalen Veranstalterkomitees und der ÖGNER hoffe ich, Ihnen ein attraktives Programm bieten zu können und wünsche Ihnen eine abwechslungsreiche und interessante Veranstaltung.



Hannes Deutschmann  
Tagungspräsident 2017  
Präsident der ÖGNER

Lokales Organisationskomitee

OA Dr. Michael Augustin

FA Dr. Ulrike Wießpeiner

# Referenten & Vorsitzende

**Augustin**, Dr. Michael, Graz, AT

**Berlis**, Univ.-Prof. Dr. Ansgar,  
Augsburg, DE

**Brodmann**, ao. Univ.-Prof. Dr. Marianne,  
Graz, AT

**Chapot**, Prof. Dr. Rene, Essen, DE

**Chemelli**, Prim. Univ.-Prof. Dr. Andreas,  
Mödling, AT

**Dazinger**, Dr. Florian, Innsbruck, AT

**DePaoli**, Dr. Luca, Klagenfurt, AT

**Deutschmann**, Univ.-Prof. Priv.-Doz. Dr.  
Hannes, Graz, AT

**Dörfler**, Univ.-Prof. Dr. Arnd, Erlangen, DE

**Egger**, Dr. Karl, Freiburg, DE

**Engelhorn**, Univ.-Prof. Dr. Tobias,  
Erlangen, DE

**Fazekas**, Univ.-Prof. Dr. Franz, Graz, AT

**Fiehler**, Prof. Dr. Jens, Hamburg, DE

**Gizewski**, Univ.-Prof. Dr. Elke,  
Innsbruck, AT

**Gutmann**, Ingomar, BSc, Wien, AT

**Hausegger**, Prim. Univ.-Prof. Dr. Klaus,  
Klagenfurt, AT

**Holtmannspötter**, Dr. Markus,  
Kopenhagen, DK

**Jehna**, Dr. Margit, Graz, AT

**Kasprian**, Assoz.-Prof. PD Dr. Gregor,  
Wien, AT

**Kau**, Prim. Dr. Thomas, Villach, AT

**Kemmling**, Dr. André, Lübeck, DE

**Killer-Oberpfalzer**, Univ.-Prof. Dr.  
Monika, MA, Salzburg, AT

**Klausner**, Dr. Fritz, Salzburg, AT

**Klein**, ao. Univ.-Prof. Dr. Günther Erich,  
Graz, AT

**Kleiser**, Priv.-Doz. Dr. Raimund, Linz, AT

**Kurre**, Priv.-Doz. Dr. Wiebke, Passau, DE

**Lamin**, Dr. Saleh, GB

**Liebig**, Univ.-Prof. Dr. Thomas, Berlin, DE

**McCoy**, Priv.-Doz. Dr. Mark, Salzburg, AT

**Mikolits**, Tanja, Graz, AT

**Mirza**, Dr. Mahmood, Galway, IE

**Möhlenbruch**, Dr. Markus,  
Heidelberg, DE

**Mokry**, Univ.-Prof. Dr. Michael, Graz, AT

**Našel**, Prim. Univ.-Prof. Dr. Christian,  
MSc, PhD, Tulln, AT

**Niederkorn**, Univ.-Prof. Dr. Kurt, Graz, AT

**Prayer**, Univ.-Prof. Dr. Daniela, Wien, AT

**Reishofer**, Priv.-Doz. Dr. Gernot, Graz, AT

**Schmidt**, Univ.-Prof. Dr. Reinhold,  
Graz, AT

**Schocke**, Univ.-Prof. Dr. Michael, Ulm, DE

**Schoder**, ao. Univ.-Prof. Dr. Maria,  
Wien, AT

**Sonnberger**, Dr. Michael, Linz, AT

**Steiger**, Dr. Ruth, Innsbruck, AT

**Taschner**, Univ.-Prof. Dr. Christian,  
Freiburg, DE

**Trenkler**, Prim. Dr. Johannes, Linz, AT

**Wanke**, Univ.-Prof. Dr. Isabel, Zürich, CH

**Wießpeiner**, Dr. Ulrike, Graz, AT

**Wiest**, Univ.-Prof. Dr. Roland, Bern, CH

**Wimmer**, Dr. Sibylle, Linz, AT

08:30 Registrierung

## SCHLAGANFALL 1

Vorsitz: Trenkler, Johannes; Linz

09:00 Begrüßung

Deutschmann, Hannes; Graz

09:10 Patientenselektion zur mechanischen Thrombektomie:

Was nicht in den Studien steht

Deutschmann, Hannes; Graz

09:30 ASPECTS, e-ASPECTS, MR ASPECTS: Einfluss auf die Entscheidungsfindung

Hausegger, Klaus; Klagenfurt

09:50 Bildgebung beim Schlaganfall: Stellenwert der Kollateraldarstellung

Engelhorn, Tobias; Erlangen

10:10 Mechanische Thrombektomie bei distalen Verschlüssen:

bildgebungsgestützte Entscheidungsfindung

Našel, Christian; Tulln

10:30 Kaffeepause

mit freundlicher Unterstützung von Abbott

## SCHLAGANFALL 2

Vorsitz: Liebig, Thomas; Berlin

11:00 It all depends on the clot: influence of clot behaviour on mechanical thrombectomy

Mirza, Mahmood; Galway, Ireland

11:20 Mechanische Thrombektomie - saugen oder retrieven?

Trenkler, Johannes; Linz

11:35 Endovaskuläre Schlaganfallbehandlung: New Devices

Gizewski, Elke; Innsbruck

11:50 Mechanische Thrombektomie - Vorgehen bei Tandemläsionen

Liebig, Thomas; Berlin

12:05 Akuter Schlaganfall - Bridging oder nicht?

Nieder Korn, Kurt; Graz

Diskussion

12:30 Mittagspause

mit freundlicher Unterstützung von Stryker

## SCHLAGANFALL 3

Vorsitz: Deutschmann, Hannes; Graz | Schoder, Maria; Wien

- 13:30 Endovaskuläre Schlaganfallbehandlung:  
Workflow, Organisation und Trainingsaspekte  
Dörfler, Arnd; Erlangen
- 13:50 Mechanische Thrombektomie - Analgosedierung vs. Intubation  
(SIESTA, GOLIATH, AnStroke)  
Möhlenbruch, Markus; Heidelberg
- 14:10 Endovaskuläre Schlaganfallbehandlung: Interessante Fälle 1  
Sonnberger, Michael; Linz
- 14:25 Endovaskuläre Schlaganfallbehandlung: Interessante Fälle 2  
De Paoli, Luca; Klagenfurt
- 14:40 Mechanische Thrombektomie 2017 - Leitlinien (EROICAS, HERMES..)  
Fiehler, Jens; Hamburg  
  
Diskussion
- 15:00 Kaffeepause

## STENOSEN UND INTERVENTIONSMANAGEMENT

Vorsitz: Gizewski, Elke; Innsbruck | Klein, Günther Erich; Graz

- 15:30 Stentimplantation bei intrakraniellen Stenosen: Wo stehen wir?  
Kurre, Wiebke; Passau
- 15:50 Carotid Artery Stenting: Update  
Deutschmann, Hannes; Graz
- 16:05 4D CTA in der Neuroradiologie  
Wießpeiner, Ulrike; Graz
- 16:20 Komplikationsmanagement bei Leistenpunktionen  
Chemelli, Andreas; Baden-Mödling

## Symposium Medtronic

Pipeline™ Shield for the treatment of intracranial aneurysms:  
description of new technology and clinical experience

Lamin, Saleh; UK



# A UNIQUE STROKE PORTFOLIO


Solitaire™ 2  
Revascularization  
Device



Cello™ Balloon  
Guide Catheter




Micro Catheter



Arc™ Support  
Catheter Series



Avigo™ Guidewire



IMPORTANT: Please refer to the package insert for complete instructions, contraindications, warnings and precautions.

© 2016 Medtronic. All rights reserved. Medtronic, Medtronic logo and Further Together are trademarks of Medtronic. All other brands are trademarks of a Medtronic company. UC201701354 EE

**Medtronic**  
Further Together

## ANEURYSMA I

Vorsitz: Holtmannspötter, Markus; Kopenhagen

- 09:00 Management von nicht-rupturierten Aneurysmen: ist Observanz sicher?  
Wanke, Isabel; Zürich
- 09:20 Behandlung breitbasiger Aneurysmen mittels T oder half-T Stenting  
Chapot, René; Essen
- 09:40 Hydrogel vs Platinumcoils - Ergebnisse der GREAT Studie  
Taschner, Christian; Freiburg
- 09:55 Behandlung komplexer Aneurysmen  
Berlis, Ansgar; Augsburg
- 10:10 Aktuelles aus der Aneurysmachirurgie  
Mokry, Michael; Graz
- 10:30 Kaffeepause

## ANEURYSMA 2 UND AFV/AVF

Vorsitz: Chapot, René; Essen

- 11:00 Flow Diverter zur Behandlung cerebraler Aneurysmen: aktuelle Datenlage  
Holtmannspötter, Markus; Kopenhagen
- 11:20 New Devices in der Aneurysmabehandlung - intrasacculäre flow diverter  
Killer-Oberpfalzer, Monika; Salzburg
- 11:40 Neue Perspektiven in der Behandlung von cerebralen AVM´s durch transvenösen Zugang  
Chapot, René; Essen
- 12:00 Embolisation cerebraler AVM/AVF mit neuen Emboisaten  
Berlis, Ansgar; Augsburg
- 12:20 Diskussion

## LUNCHSYMPOSIUM MICROVENTION „WEB IN ÖSTERREICH“

Vorsitz: Deutschmann, Hannes; Graz

- Fiehler, Jens; Hamburg | Hausegger, Klaus; Klagenfurt | Trenkler, Johannes; Linz
- 12:30 Mittagspause  
mit freundlicher Unterstützung von Microvention



# ENTZÜNDLICHE UND DEMYELINISIERENDE ERKRANKUNGEN DES GEHIRNS, RÜCKENMARKES UND DER PERIPHEREN NERVEN UND DIVERSES I

Vorsitz: Gizewski, Elke; Innsbruck

- 13:30 Entzündliche Erkrankungen des Rückenmarkes: Update  
Prayer, Daniela; Wien
- 13:55 Multiple Sklerose: aktuelle Nomenklatur und Klassifikation  
Fazekas, Franz; Graz
- 14:20 „Was uns auf die Nerven geht ...“ - Periphere Neuropathien  
im Überblick  
Wimmer, Sybille; Linz
- 14:40 Akute MR Veränderungen im Rahmen des status epilepticus  
McCoy, Mark; Salzburg
- 15:00 Kaffeepause  
mit freundlicher Unterstützung von Medtronic

## DIVERSES II

Vorsitz: McCoy, Mark; Salzburg

- 15:30 Periinterventionelles Gerinnungsmanagement - NOAKs, Prasugrel...  
and more  
Brodmann, Marianne; Graz
- 15:50 Cerebrale Mikroangiopathie  
Schmidt, Reinhold; Graz
- 16:10 MR Artefakte in der Neuroradiologie  
Klausner, Fritz; Salzburg
- 16:25 Mikrostrukturelle Schäden und Eisenüberladung bei  
Parkinsonsyndromen: Ergebnisse der multimodalen MRT  
Schocke, Michael; Ulm
- 16:45 Möglichkeiten der MR Bildgebung mittels SWI  
Kau, Thomas; Villach  
  
Diskussion

## SCHLAGANFALL UND ANEURYSMA WORKSHOP (BEGRENZTE TEILNEHMERANZAHL)

15:30 Allgemeine Einführung in die endovaskuläre Schlaganfallbehandlung mittels mechanischer Thrombektomie, Behandlung von zerebralen Aneurysmen, Materialkunde

Tutoren:

Augustin, Michael; Graz | Deutschmann, Hannes; Graz | Gizewski, Elke; Innsbruck | Sonnberger, Michael; Linz | Trenkler, Johannes; Linz | Mikolits, Tanja; Graz

**Station 1:** Microvention: Materialkunde und Technik - Aneurysmabehandlung und mechanische Thrombektomie

**Station 2:** Stryker: Materialkunde und Technik - mechanische Thrombektomie und Aneurysmabehandlung

**Station 3:** Medtronic: Simulatortraining - mechanische Thrombektomie und Aneurysmabehandlung

**Station 4:** Novomed/phenox: Aneurysma Behandlung am 3D Flussmodell (Kemmling, André; Schleswig-Holstein)

**Station 5:** Penumbra: Materialkunde und Technik - mechanische Thrombektomie


Freitag, 17.11.



# LIPIODOL® ULTRA FLUID

Ethyl ester of iodized fatty acids of poppy seed oil

## Lipiodol® efficacy & safety for improved overall survival in HCC<sup>1,3,5,6</sup>



**LIPIODOL® ULTRA-FLUID. Composition:** Ethyl ester of iodized fatty acids of poppy seed oil 10 ml, corresponding to an iodine content of 480 mg/ml. **Indications<sup>(\*)</sup>** In diagnostic radiology: Hysteroangiography. Ascending urography - lymphography - Sialography - Radiography and exploration of abscesses - Exploration of frontal sinuses - Pre and post-operative cholangiography. In interventional radiology: - Visualization and localization by selective intra-arterial use during CT of liver lesions in adults with known or suspected hepatocellular carcinoma. - Visualization, localization and vectorization during Trans-Arterial Chemo-Embolization (TACE) of hepatocellular carcinoma at intermediate stage, in adults - Selective embolization in conjunction with histocry glue (particularly for arteriovenous malformation or aneurysms). - Selective injections of LIPIODOL® ULTRA-FLUID into the hepatic artery for diagnostic purposes where a spot CT scan is not practical. In endocrinology: Prevention of severe cases of iodine deficiency. **Posology and method of administration<sup>(\*)</sup>** have to be adapted according to the type of examination, the venous embolized, the age and weight of the patient. The volume to be administered depends on the particular requirements of the technique and the size of the patient. **Contraindications:** Hypersensitivity to LIPIODOL® ULTRA-FLUID. Confirmed hyperthyroidism. Patients with traumatic injury, recent haemorrhage or bleeding. - **Hypersensitivity** during pregnancy or acute pelvic inflammation - **Radiotherapy** in interventional radiology (Trans-Arterial Chemo-Embolization). Administration in liver areas with altered bile ducts unless drainage has been performed. **Special warnings and special precautions for use<sup>(\*)</sup>** There is a risk of hypersensitivity regardless of the dose administered. - **Lymphography:** Pulmonary embolism may occur immediately or after few hours to days from inadvertent systemic vascular injection or intravascular of LIPIODOL® ULTRA-FLUID. Perform radiological monitoring during LIPIODOL® ULTRA-FLUID injection and avoid use in patients with severely impaired lung function, cardiopulmonary failure or right sided cardiac overload. - **Hypersensitivity:** all iodinated contrast agents can lead to more or major hypersensitivity reactions, which can be life-threatening. These hypersensitivity reactions are all an allergic nature (known to anaphylactic reactions if they are anaphylactic in nature). They can be immediate (occurring within 60 min) or delayed (not occurring until up to 7 days later). Anaphylactic reactions are immediate and can be fatal. They are dose-independent, can occur right from the first administration of the product, and are often unpredictable. Avoid use in patients with a history of sensitivity to other iodinated contrast agents, bronchial asthma or allergic disorders because of an increased risk of a hypersensitivity reaction to LIPIODOL® ULTRA-FLUID. **Interf.** can cause hyperkalemia in preoperated patients. Lymphography softens the fibrinoid with iodine for several months and fibrinoid absorption should be performed before radiological examination. **Chemo-Embolization:** Trans-Arterial Chemo-Embolization is not recommended in patients with decompressed liver cirrhosis (Child-Pugh B3), advanced liver dysfunction, metastatic invasion and/or extrahepatic spread of the tumor. Renal insufficiency must be prevented by correct hydration before and after the procedure. Ophthalmologic services must be carefully monitored. Hepatic interventional treatment can progressively cause an irreversible liver insufficiency in patients with serious liver dysfunction and/or undergoing dose multiple sessions. The risk of superinfection in the treated area is normally prevented by administration of antibiotics. **Embolization with glue:** An early polymerisation reaction may exceptionally occur between LIPIODOL® ULTRA-FLUID and certain surgical glues, or even certain lotions of glue, before using new batches of LIPIODOL® ULTRA-FLUID or surgical glue, the compatibility of LIPIODOL® ULTRA-FLUID and the glue must be tested in *in vitro*. **Interaction with other medicinal products and other forms of interaction<sup>(\*)</sup>** The following: beta-blockers, vasodilators (nitroglycerin, angiotensin-converting enzyme inhibitors, angiotensin-receptor antagonists, diuretics, beta-lactams). **Female pregnancy and lactation<sup>(\*)</sup>** LIPIODOL® ULTRA-FLUID must not be used in pregnant women if absolutely necessary and under strict medical supervision. Breastfeeding should be discontinued if LIPIODOL® ULTRA-FLUID must be used. **Effects on the ability to drive and use machines:** The effects on the ability to drive and to use machines have not been investigated. **Undesirable effects<sup>(\*)</sup>** may adverse effects are dose-related and dosage should therefore be kept as low as possible. Hypersensitivity, anaphylactic reaction, anaphylactoid reaction, vomiting, diarrhea, nausea, fever, pain, Arterial, cough, hypotension, hyperkalemia, fibrinoid, pulmonary embolism, cerebral embolism, central vein thrombosis, hemodynamic depression, hepatic vein thrombosis, aneurysms. **One dose<sup>(\*)</sup>** The total dose of LIPIODOL® ULTRA-FLUID administered must not exceed 50 ml. **Pharmaco-medicinal properties<sup>(\*)</sup>** **Pharmacotherapeutic group:** X-ray contrast media, iodinated. ATC code: V08A D01. Water-soluble iodinated contrast medium. **Presentation<sup>(\*\*)</sup>** 10 ml glass ampoule, box of 1 - 10 ml glass ampoule, box of 30. **Marketing authorization holder<sup>(\*)</sup>** Guerbet - BP 57400 - F-95943 Essay G&C cedex - FRANCE. **Information<sup>(\*)</sup>** 1 - 33 (0) 45 91 50 00. **Revision:** September 2, 2015.

<sup>(\*)</sup> For complete information please refer to the local Summary of Product Characteristics

<sup>(\*\*)</sup> Indications, volumes and presentations may differ from country to country.

<sup>(\*\*\*)</sup> Reporting of suspected adverse reactions is important as it helps to continuously assess the benefit/risk balance. Therefore, Guerbet encourages you to report any adverse reactions to your health authorities or to our local Guerbet representative.

1. Ikeda M, et al. Prospective Study of Transarterial Arterial Chemoembolization for Unresectable Hepatocellular Carcinoma: An Asian Cooperative Study between Japan and Korea. J. Vasc. Interv. Radiol. 2012; 24: 490-500
2. Gu CM, et al. Randomized Controlled Trial of Transarterial Lipiodol Chemoembolization for Unresectable Hepatocellular Carcinoma. Hepatology 2002; 35: 1154-1171
3. Llovet JM, et al. Arterial embolization or chemoembolization versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomized controlled trial. The Lancet 2002; 359: 1734-1739
4. Llovet JM, et al. Systematic Review of Randomized Trials for Unresectable Hepatocellular Carcinoma. Chemoembolization Improves Survival. Hepatology 2003; 37: 429-442
5. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J. Hepatol. 2012; 56: 939-946
6. Joint Society of Hepatology Recommendations, Chapter 4. Hepatology Research 2010; 43 (Suppl 1): 96-112
7. Brink J, & Sherman M. AASLD Practice Guidelines: American Association for Study of the Liver Diseases. Hepatology 2011; 53: 1020-1022
8. Chinese guidelines 2011 edition. Chin. Clin. Oncol. 2012; 1:10

## DIFFUSIONSBILDGEBUNG UND DTI - BEGINN ODER ENDE EINER ERFOLGSGESCHICHTE?

Vorsitz: Prayer, Daniela; Wien

- 09:00 **Basis der Diffusionsbildgebung**  
Kasprian, Gregor; Wien | Gutmann, Ingomar; Wien
- 09:20 **Neue Methoden im MRT: "Diffusion Mesoscopic Imaging"**  
Egger, Karl; Freiburg
- 09:40 **Bedeutung und Limitationen des BOLD und DT Imaging bei Tumor- und EpilepsiepatientInnen im diagnostisch-therapeutischen Bereich**  
Kleiser, Raimund, Linz | Wimmer, Sibylle; Linz
- 10:10 **Fraktale Analyse der MR Traktographie zeigt altersabhängige Veränderungen der weißen Substanz**  
Reishofer, Gernot; Graz
- 10:30 Kaffeepause

## DIVERSE THEMEN

Vorsitz: Našel, Christian; Tulln

- 11:00 **Zerebrale Veränderungen nach Elektrokonvulsionstherapie bei Depression**  
Jehna, Margit; Graz
- 11:15 **Schmerzforschung im fMRI**  
Gizewski, Elke; Innsbruck
- 11:35 **Anorexie**  
Steiger, Ruth; Innsbruck
- 11:50 **CT gesteuerte periradikuläre Infiltrationen und Blutpatch Anlage bei Liquorunterdrucksyndrom**  
Dazinger, Florian; Innsbruck
- 12:05 **Machine Learning und Postprocessing**  
Wiest, Roland; Bern
- 12:25 **Arthur-Schüller Preis Verleihung - Ehrenvortrag**
- 12:40 **Verabschiedung - Ende der Tagung**
- 12:45 **Vollversammlung der ÖGNR**  
Diskussion

# Sponsoren

Wir bedanken uns sehr herzlich bei unseren Sponsoren und Ausstellern

## Goldsponsor



## Silbersponsor



## Bronzesponsor



# Aussteller

a.m.p. Angerler Medizin Produkte

Acandis

amacord

Bayer Austria

Bracco

Medtronic

Microvention

Neuravi

Novomed | phenox

Olea Medical

Penumbra

plus medica

Siemens Healthcare Diagnostics

Stryker

# Allgemeines

## KONGRESSVERANSTALTER

Univ.-Prof. Priv.-Doz. Dr. Hannes Deutschmann

Abteilungsleiter

Klinische Abteilung für Neuroradiologie, vaskuläre und interventionelle Radiologie

Universitätsklinik für Radiologie

Auenbruggerplatz 9

8036 Graz

Tel.: +43 (0)316-385-83271

E-Mail: hannes.deutschmann@medunigraz.at

## WISSENSCHAFTLICHE LEITUNG UND ORGANISATION

Univ.-Prof. Priv.-Doz. Dr. Hannes Deutschmann

Lokales Organisationskomitee

OA. Dr. Michael Augustin

FA. Dr. Ulrike Wießpeiner

## KONGRESSESEKRETARIAT

admicos.Congress Incentive GmbH

Skodagasse 14-16

1080 Wien

Mag. Stefan Böhm-Jurkovic

Tel.: +43 (0)1-512 80 91-11

E-Mail: jurkovic@admicos.com

## TAGUNGsort

Alte Universität Graz

Hofgasse 14

8010 Graz

## KONGRESS- UND AUSSTELLUNGSTERMIN

Donnerstag 16. November bis Samstag 18. November 2017

Für die Teilnahme am Kongress werden 21 DFP-Punkte vergeben.

# building the future together

A wider portfolio  
for a complete solution



Distributed by: plus medica GmbH

Klingerstraße 9 . 2353 Guntramsdorf . Österreich . Tel: +43 1 50 32 585 . Fax: +43 1 50 32 589  
info@plusmedica.at . www.plusmedica.org



## Success accelerated.

Trevo Stroke Solutions™ is a comprehensive product portfolio designed to work together to quickly remove the clot – helping you find the **right approach for revascularization** in a wide range of patient and anatomical needs.



## Trevo Stroke Solutions™

### Trevo™ XP ProVue Retrievers

**INDICATIONS FOR USE** The Trevo Retriever is intended to restore blood flow in the neurovasculature by removing thrombus in patients experiencing ischemic stroke within 8 hours of symptom onset. Patients who are ineligible for intravenous tissue plasminogen activator (IV t-PA) or who fail IV t-PA therapy are candidates for treatment.

### AXS Catalyst™ Distal Access Catheter

**INTENDED USE/INDICATIONS FOR USE** The AXS Catalyst Distal Access Catheter is indicated for use in facilitating the insertion and guidance of appropriately sized interventional devices into a selected blood vessel in the peripheral and neurovascular systems. It is also indicated for the removal/aspiration of soft emboli and thrombi from vessels in the peripheral and neurovasculature.

### FlowGate™ Balloon Guide Catheter

**INDICATIONS FOR USE** FlowGate™ Balloon Guide Catheters are indicated for use in facilitating the insertion and guidance of an intravascular catheter into a selected blood vessel in the peripheral and neurovascular systems. The balloon provides temporary vascular occlusion during these and other angiographic procedures. The Balloon Guide Catheter is also indicated for use as a conduit for Retrieval devices.

### THIS DOCUMENT IS INTENDED SOLELY FOR THE USE OF HEALTHCARE PROFESSIONALS.

A physician must always rely on his or her own professional clinical judgment when deciding whether to use a particular product when treating a particular patient. Stryker does not dispense medical advice and recommends that physicians be trained in the use of any particular product before using it in a procedure. The information presented is provided to demonstrate the breadth of Stryker product offerings. A physician must always refer to the package insert, product label and/or instructions for use before using any Stryker product. Products may not be available in all markets because product availability is subject to the regulatory and/or medical practices in individual markets. Please contact your Stryker representative if you have questions about the availability of Stryker products in your area. The Stryker products listed above are CE marked according to the Medical Device Directive 93/42/EEC.